Skip to main content

Table 1 The basic information and data of all included studies in the meta-analysis

From: Prognostic significance of platelet-to-lymphocyte ratio in urothelial carcinoma patients: a meta-analysis

Author

Year

Country

No. of patients

Sex (M/F)

Tumor type

Age (years)

Median (range)

Cut-off value

Survival analysis

Treatment

NOS score

Kim

2015

Korea

277

218/59

UTUC

63.7 (29.5–90)

150

CSS, DFS

NUx

7

Zhang

2015

China

124

100/24

BC

65 (30–78)

140

OS

RC

8

Song

2016

China

140

86/54

UTUC

67 (39–81)

128

DFS, PFS

RNU

6

Altan

2017

Turkey

113

86/27

UTUC

63.7

150

DFS, PFS

RNU

7

Dalpiaz

2017

Austria

180

109/71

UTUC

70

150

OS, PFS

RNU

8

Huang

2017

China

481

311/170

UTUC

65 (30–89)

241

OS, PFS

RNU

7

Kang

2017

Korea

1551

1302/249

BC

65 (57–72)

124

OS, CSS

TURB

7

Mao

2017

China

207

169/38

BC

66 (59–80)

123

DFS, PFS

TURB

8

Miyake

2017

Japan

117

95/22

BC

72

150

OS, CSS

RC

8

Rajwa

2018

Poland

144

NA

BC

NA

161

OS, CSS

RC

6

Son

2018

Korea

1137

825/312

UTUC

69

142

DFS, PFS

RNU

6

Itami

2019

Japan

125

96/29

UTUC

72 (38–90)

150

OS, DFS

NUx

7

Kuroda

2019

Japan

187

138/49

UTUC

71 (38–90)

165

DFS, PFS

RNU

7

Yuk

2019

Korea

385

327/58

BC

72.6

171

OS, CSS

TURB

7

Zhu

2019

China

186

157/29

BC

65

111

OS

RC

7

  1. OS overall survival, DFS disease-free survival, PFS progression-free survival, CSS cancer-specific survival, NUx nephroureterectomy, RC radical cystectomy, RNU radical nephroureterectomy, TURB transurethral resection of bladder tumor, NA not available, NOS Newcastle–Ottawa Scale, UTUC upper tract urothelial carcinoma, BC bladder cancer